Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Naphthalene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.42 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.39 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 7/20 | 0.80 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naphthalene SCHEMBL27495716 | 1.00 | CYP2A6 (0.80) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL27908546 | 1.00 | CYP2A6 (0.80) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL430345 | 1.00 | CYP2A6 (0.80) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL308599 | 0.95 | CYP2A6 (0.89) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL15817793 | 0.95 | CYP2A6 (0.89) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL5950130 | 0.95 | CYP2A6 (0.89) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL184189 | 0.95 | CYP2A6 (0.89) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL8525098 | 0.95 | CYP2A6 (0.89) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL20578254 | 0.95 | CYP2A6 (0.89) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR | |
| Naphthalene SCHEMBL5950127 | 0.95 | CYP2A6 (0.89) | CYP2A6ALOX12ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109765327-B | Sampling device for detecting coke oven flue gas components | 中冶焦耐(大连)工程技术有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20080227854-A1 | Compound 3-(1, 1-Dimethyl-Allyl)-6-Hydroxy-Chromen-2-One and its Pharmaceutically Acceptable Salts Thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-09-18 | — | — | US | disclosed |
| EP-0730451-A4 | BLOCKING UTILIZATION OF TETRAHYDROBIOPTERIN TO BLOCK INDUCTION OF NITRIC OXIDE SYNTHESIS | CORNELL RES FOUNDATION INC (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6103888-A | HUMAN CDNA HAVING SPECIFIC NUCLEOTIDE SEQUENCE OR COMPLEMENTARY SEQUENCE; FOR RECOMBINANT PRODUCTION OF PROTEINS FOR TREATMENT AND DIAGNOSIS OF GRAMNEGATIVE SEPSIS; TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION | PANORAMA RESEARCH, INC. (US) | 2000-08-15 | — | — | US | disclosed |
| US-5874433-A | Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0746605-A4 | MAMMALIAN CATIONIC PROTEINS HAVING LIPOPOLYSACCHARIDE BINDING AND ANTI-COAGULANT ACTIVITY | PANORAMA RES INC (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5618675-A | EXPOSING SAMPLE TO A SPECIFIC POLYPEPTIDE WHICH BINDS LIPOPOLYSACCHARIDE, DETECTING BINDING; USEFUL FOR DIAGNOSIS OF GRAMNEGATIVE SEPSIS, ENDOTOXIN SHOCK OR DISSEMINATED INTRAVASCULAR COAGULATION | PANORAMA RESEARCH, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0746605-A1 | MAMMALIAN CATIONIC PROTEINS HAVING LIPOPOLYSACCHARIDE BINDING AND ANTI-COAGULANT ACTIVITY | PANORAMA RESEARCH, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0730451-A1 | BLOCKING UTILIZATION OF TETRAHYDROBIOPTERIN TO BLOCK INDUCTION OF NITRIC OXIDE SYNTHESIS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5502050-A | DIHYDROXYPHENYL-SUBSTITITED PYRIDINES OR QUINONES, HYPERTENSIVE AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995014468-A1 | BLOCKING UTILIZATION OF TETRAHYDROBIOPTERIN TO BLOCK INDUCTION OF NITRIC OXIDE SYNTHESIS | CORNELL RESEARCH FOUNDATION INC. (US) | 1995-06-01 | — | — | WO | disclosed |
| WO-1994002589-A1 | MAMMALIAN CATIONIC PROTEINS HAVING LIPOPOLYSACCHARIDE BINDING AND ANTI-COAGULANT ACTIVITY | PANORAMA RESEARCH, INC. (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227854-A1 | Compound 3-(1, 1-Dimethyl-Allyl)-6-Hydroxy-Chromen-2-One and its Pharmaceutically Acceptable Salts Thereof | NOS3, NOS2, NOS1 | CA2 271/4885GLA 1227/4885ACHE 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.